EcoDrugPlus

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSORLG00000012686
Gene Symbol: EGLN1
4 Cross references
220 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 2

Ensembl ID : ENSORLG00000006962
Gene Symbol: EGLN2
3 Cross references
191 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 3

Ensembl ID : ENSORLG00000018068
Gene Symbol: EGLN3
4 Cross references
198 Possible Orthologues:

Endothelial Pas Domain Protein 1b

Ensembl ID : ENSORLG00000003535
Gene Symbol: EPAS1B
4 Cross references
210 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSORLG00000017044
Gene Symbol: ECE1
4 Cross references
230 Possible Orthologues:

Endothelin Receptor Type Aa

Ensembl ID : ENSORLG00000007423
Gene Symbol: EDNRAA
4 Cross references
205 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSORLG00000017775
Gene Symbol: LOC100049225
3 Cross references
196 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSORLG00000011054
Gene Symbol: EDNRB
4 Cross references
195 Possible Orthologues:

Endothelin-1 Receptor

Ensembl ID : ENSORLG00000027065
Gene Symbol: LOC101172686
4 Cross references
197 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSORLG00000003066
Gene Symbol: EZH2
3 Cross references
229 Possible Orthologues:

Epidermal Growth Factor Receptor A (Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog, Avian)

Ensembl ID : ENSORLG00000017692
Gene Symbol: EGFRA
4 Cross references
212 Possible Orthologues:

Epoxide Hydrolase 2, Cytoplasmic

Ensembl ID : ENSORLG00000001624
Gene Symbol: EPHX2
3 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).